Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon

Cardinal Health MynxGrip Vascular Closure Device receives Food and Drug Administration approval for venous indication

Cardinal Health today announced that its MynxGrip® Vascular Closure Device recently received Food and Drug Administration approval for use to close femoral veins. The MynxGrip device is now indicated for use to seal 5F, 6F and 7F femoral arterial and femoral venous access sites.

Thumbnail

Patients with nonobstructive CAD still at risk for MI, death

Coronary artery disease (CAD) may not have to be obstructive to increase patients’ risks for MI or all-cause mortality. According to a study published online Nov. 4 in JAMA, patients diagnosed with nonobstructive CAD through coronary angiography were two times more likely to experience MI within one year of diagnosis as those with no apparent CAD. 

Covidien’s HawkOne Directional Atherectomy System receives FDA 510(K) clearance for the treatment of peripheral arterial disease

Covidien plc (NYSE: COV) today announced U.S. Food and Drug Administration 510(k) clearance for the HawkOne™ directional atherectomy system. The latest addition to Covidien’s directional atherectomy portfolio, the HawkOne system provides physicians with an enhanced cutting mechanism to more effectively treat the widest variety of plaque in patients with peripheral arterial disease (PAD).

Thumbnail

Spectranetics offers $30M for PAD balloon

Spectranetics will pay $30 million to acquire a drug-coated angioplasty balloon platform from Covidien, if the transaction passes muster with regulators.

Two 2nd-gen drug-eluting stents equally safe, effective at 3 years

Three-year outcomes post-stenting reveal favorable and similar results for patients with and without bifurcated lesions treated with second-generation drug-eluting stents. 

Cardiovascular Systems receives CE mark for Stealth 360 Peripheral Orbital Atherectomy System

Cardiovascular Systems, Inc. today announced that it has received CE (Conformité Européenne) Mark for its Stealth 360º Orbital Atherectomy System (OAS). Stealth 360 is a percutaneous OAS that is indicated to treat patients who suffer from peripheral arterial disease (PAD).

Higher risk of bleeds with dabigatran but lower risk of brain hemorrhage

Blacks and patients with impaired kidney function may be particularly at risk of bleeding if given the anticoagulant dabigatran, according to an analysis of Medicare data. Compared with warfarin, dabigatran had higher bleeding risks overall but a lower risk of intracranial hemorrhage.

Medtronic launches Resolute Onyx Drug-Eluting Stent following CE mark

Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations, Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européene) mark and international launch of the Resolute Onyx Drug-Eluting Stent (DES). The first live patient implant of the Resolute Onyx DES occurred recently during the XII International Course of Endovascular and Myocardial Therapy in Madrid, Spain. The Resolute Onyx Drug-Eluting Stent is not approved in the United States.

Displaying 7145 - 7152 of 10742

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.